(24/7 MARKET NEWS) – Cardio Diagnostics Holdings Inc (Nasdaq: CDIO) announced, this morning, that it’s launching its PrecisionCHD integrated epigenetic-genetic blood test for the early detection of coronary heart disease.
Cardio Diagnostics is at $2.40, up $1.0652 (+79.80%), on 1.5 million premarket shares.
Its 52-week trading range is $0.7966 to $10.25. It’s cleared all of its recent resistance levels, with the exception of its February trading levels. It may just be a repeat of that day’s trading, but it feels like it should move of today’s gains.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
